What is CAR T-cell therapy for myeloma?

• CAR T Cells: Engineering Patients’ Immune Cells to Treat Their Cancers

When to consider CAR T-cell therapy? 

• FDA approves ciltacabtagene autoleucel for relapsed or refractory multiple myeloma
• CARs Moving Forward: The Development of CAR T-Cell Therapy in the Earlier Treatment Course of Hematologic Malignancies 

FDA-approved myeloma CAR T-cell therapies

• Carvykti Prescribing Information
• The Carvykti Treatment Process
• Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma
• Ciltacabtagene autoleucel (cilta-cel) vs standard of care (SOC) in patients (pts) with relapsed/refractory multiple myeloma (MM): CARTITUDE-4 survival subgroup analyses
• FDA Approval Summary: Idecabtagene Vicleucel for the Treatment of Triple-Class-Exposed, Relapsed or Refractory Multiple Myeloma
• U.S. FDA Approves Bristol Myers Squibb and 2seventy bio’s Abecma for Triple-Class Exposed Relapsed or Refractory Multiple Myeloma After Two Prior Lines of Therapy
• How will I receive ABECMA?

Side effect management of CAR T-cell therapy for multiple myeloma

• Cytokine release syndrome
• Grading of cytokine release syndrome associated with the CAR T cell therapy
• Immune effector cell associated neurotoxicity syndrome in chimeric antigen receptor-T cell therapy
• CAR T-Cell Grading and Management: ICANS
• In the Eye of the Storm: Immune-mediated Toxicities Associated With CAR-T Cell Therapy
• Cytopenia after CAR-T Cell Therapy—A Brief Review of a Complex Problem
• Managing Fatigue, Anemia, and GI Side Effects with Nutrition
• Cytopenia
• Vaccine schedule recommendations and updates for patients with hematologic malignancy post‐hematopoietic cell transplant or CAR T‐cell therapy
• Your questions about BCMA and multiple myeloma, answered
• Recommendations on Prevention of Infections during Chimeric Antigen Receptor T-Cell and Bispecific Antibody Therapy in Multiple Myeloma
• Best Practice Considerations by The American Society of Transplant and Cellular Therapy: Infection Prevention and Management After Chimeric Antigen Receptor T Cell Therapy for Hematological Malignancies
• Immune effector cell-associated neurotoxicity syndrome (ICANS) and other neurologic toxicities of CAR-T cell and related therapies
• Cytopenias in BCMA CAR T: unraveling inflammatory mechanisms
• Potential Side Effects of CAR T-cell Therapy: Symptoms & Treatment
• New insights into CAR T-cell hematological toxicities: manifestations, mechanisms, and effective management strategies
• Nausea and vomiting

A look ahead: The future of myeloma CAR T-cell therapy

• Minimally modified off-the-shelf allogeneic CAR T cells
• Allogeneic off-the-shelf CAR T-cell therapy
• New CAR T Trial in MM Aims for Triple Receptor Targeting
• Adoptive NK Cell Therapy - a Beacon of Hope in Multiple Myeloma Treatment
• AstraZeneca pays up to $1bn for biotech firm ‘that could transform cell therapy’

Caregiver role in myeloma CAR-T

• The Role of the Caregiver
• Caregiving for CAR T Cell Therapy
• Let’s Chat CAR T: For Caregivers
• Let’s Chat CAR T: Find Support
• Overcoming Caregiver Barriers in CAR T-Cell Therapy Referrals

Communicating with your healthcare team

• Transferring Clinics: It Begins With You

Financial resources for myeloma CAR-T

• Inpatient hospital care
• Medicare Prescription drugs (outpatient)
• What Medicare Part D drug plans cover
• Medicare Chemotherapy
• CMS Oncology Care Model
• Drugs excluded from Part D coverage
• Parts of Medicare
• Inflation Reduction Act Research Series— Medicare Part D Enrollee Out-Of-Pocket Spending: Recent Trends and Projected Impacts of the Inflation Reduction Act
• Financial Considerations for CAR T-cell Therapy Patients